Abstract
Cytogenetic and molecular genetic abnormalities are critical factors in the prognosis of acute myeloid leukemia (AML), yet patients within the same risk groups often exhibit variable outcomes. Immunophenotyping remains a cornerstone of AML diagnosis due to its simplicity and universal applicability. This study aimed to identify new immunophenotypic markers for the diagnosis and prognosis of AML. We examined the expression of C-type lectin-like molecule 1 (CLL-1) in AML blasts from 52 patients and compared it with classic markers like CD33 and CD34. Our results indicate that CLL-1 is expressed on the majority of AML blasts (78.8%) and leukemic stem cells (LSCs) but is absent on normal hematopoietic stem cells (HSCs). Furthermore, low CLL-1 expression was independently associated with shorter overall survival (OS), identifying CLL-1 as a potent dual-purpose biomarker for AML.
Introduction
Acute Myeloid Leukemia (AML) is a highly heterogeneous malignancy, making it difficult to predict clinical outcomes using current genetic risk profiles alone. Standard diagnostic markers, such as CD33 and CD34, are frequently expressed on both leukemic cells and healthy hematopoietic stem cells (HSCs). This lack of specificity complicates the targeting of "cancer seeds" without damaging the patient's healthy blood-forming capacity. There is an urgent clinical need for markers that can specifically distinguish leukemic stem cells (LSCs) from healthy ones while providing reliable prognostic insights.
Methods
The study analyzed bone marrow or peripheral blood samples from 52 patients with newly diagnosed or relapsed/refractory AML at Guangdong Provincial People's Hospital.
- Immunophenotyping: Flow cytometry was employed to measure the expression levels of CLL-1, CD33, and CD34 on AML blasts and stem cell populations ($CD34^+CD38^-$).
- Comparative Analysis: CLL-1 expression was benchmarked against normal bone marrow (NBM) samples and validated using the Human Proteome Map, a public mass spectrometry database, to ensure tissue specificity.
- Survival Analysis: Patients were categorized into "CLL-1 high" and "CLL-1 low" groups based on a 59.0% expression cutoff. Kaplan-Meier curves and log-rank tests were used to evaluate Event-Free Survival (EFS) and Overall Survival (OS).
Results
A Specific and Synergistic Diagnostic Marker
CLL-1 was found on the surface of 78.8% of AML blasts. Crucially, while CLL-1 is prevalent on leukemic stem cells, it is notably absent on normal hematopoietic stem cells. This makes CLL-1 a "cleaner" target for emerging therapies, such as CAR-T cells, compared to CD33. Additionally, CLL-1 demonstrated diagnostic synergy; it often "filled the gap" in cases where standard markers like CD33 or CD34 were low, increasing overall diagnostic sensitivity.
The Prognostic Paradox
While higher expression of a cancer marker usually suggests a worse outcome, this study found a prognostic paradox: low CLL-1 expression (≤ 59%) predicted significantly poorer survival.
- Overall Survival: The CLL-1 low group had significantly shorter OS ($p = 0.012$) and EFS ($p = 0.048$) than the high-expression group.
- Treatment Resistance: In patients who failed to achieve complete remission after initial treatment, low CLL-1 expression was even more strongly associated with rapid disease progression ($p < 0.001$).
This suggests that the absence of CLL-1 may characterize a more primitive, aggressive, and treatment-resistant phenotype of the disease.
Discussion
These findings identify CLL-1 as a valuable tool for both the diagnosis and long-term management of AML. Its absence on healthy HSCs provides a therapeutic window for targeted treatments, while its expression levels offer a simple, flow-cytometry-based method for predicting patient survival.
However, the study's sample size of 52 patients necessitates larger, multi-center trials to validate the 59% cutoff for clinical use. Future research should also investigate the biological mechanisms—specifically the signaling pathways—that cause low CLL-1 expression to correlate with such aggressive disease progression.
Summary updated